CA2041774C - Use of cross-linked amylose as a matrix for the slow release of biologically active compounds - Google Patents
Use of cross-linked amylose as a matrix for the slow release of biologically active compoundsInfo
- Publication number
- CA2041774C CA2041774C CA002041774A CA2041774A CA2041774C CA 2041774 C CA2041774 C CA 2041774C CA 002041774 A CA002041774 A CA 002041774A CA 2041774 A CA2041774 A CA 2041774A CA 2041774 C CA2041774 C CA 2041774C
- Authority
- CA
- Canada
- Prior art keywords
- cross
- cla
- release
- amylose
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Abstract
ABSTRACT OF THE DISCLOSURE
The present invention is concerned with a solid slow release oral pharmaceutical dosage unit which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product and a cross-linked polymer of amylose with a cross-linking agent selected from 2,3 dibromopropanol and epichlorohydrin, wherein the cross-linking of the polymer has been carried out with from about 0.1 to about 10 g of cross-linking agent per 100 g of amylose.
The present invention is concerned with a solid slow release oral pharmaceutical dosage unit which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product and a cross-linked polymer of amylose with a cross-linking agent selected from 2,3 dibromopropanol and epichlorohydrin, wherein the cross-linking of the polymer has been carried out with from about 0.1 to about 10 g of cross-linking agent per 100 g of amylose.
Description
2~774 FIELD OF THE INVENTION
',.
~`, The present invention relates to a slow release pharmaceutical tablet, and more particularly to a slow release pharmaceutical tablet incorporating a cross-5 linked polymer of amylose as the slow release matrix.
:
' ~ PRIOR ART
- In the last two decades much interest has been paid to the10 development of monolithic devices for the controlled release of dmgs by various routes of administration.
'.., There are several types of polymers which have already been used as matrix for the release of drug. Thus, polymeric materials such as polyvinyl chloride, 1 15 polyethylene polyamides, ethylcellulose, silicone, poly(hydroxyethyl methacrylate)-J. PHEMA, other acrylic copolymers, polyvinylacetate-polyvinylchloride copolymers and other polymers were described as adequate matrix for tablet preparation (seefor example USP 3,087,860; USP 2,987,445; and Pharm. Acta Helv., 1981), 55, 174-182, Salomon et al.
The controlled or slow release of some drugs is of a high importance for biopharmaceutical applications. There are various systems of slow release, mostly based on diffusion-controlled release or swelling control release mechanisms.
- - Diffusion-controlled polymeric systems allow some prolongation of drug release but ~ 2 5 prov;de no real means of control since the release rate is not constant. ,,~, .'', ~
,.
:~"
.,;
..
. . ... :, . .: .
2~17~
Recently, many efforts have been devoted to the development of systems able to release the drug at a constant rate, in other words, following zero-order kinetics, such as described in S.T.P. Pharma 1986, 2, 3~-46 (Peppas et al.).
The approach called 'swelling-controlled' systems consists in glassy polymers into 5 which a water front penetrates at a constant rate. Behind this front, the polymer is . in a rubbery state. Provided the drug diffusion coefficient in the rubbery polymer is much higher than in the glassy polymer, a zero order release can be achieved to a certain degree. However, the delivery rate is constant only for a l;mited fraction of the release, usually around 60% of the total amount of contained drug, and l0 requires a low initial drug concentration.
Accordingly, it would be highly desirable to provi~e a slow release system following a zero-order kinetics, and allowing a controlled release of a drug : at a constant rate until all the drug is released, whatever the concentration of the 15 drug in the system is.
.' SUMMA~Y OF THE INVENTION
- In accordance with the present invention there is now provided a 20 solid slow release oral pharmaceutical dosage unit which comprises a solid dosage . unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product and a cross-linked polymer of amylose with a cross-linking .,, ~: agent selected from 2,3-dibromopropanol and epichlorohydrin, wherein the cross-linking of the polymer has been carried out with from about 0.1 to about 10 g of., :
25 cross-linking agent per 100 g of amylose.
: ;
;........................................................................... , .,~
~;
',.
~`, The present invention relates to a slow release pharmaceutical tablet, and more particularly to a slow release pharmaceutical tablet incorporating a cross-5 linked polymer of amylose as the slow release matrix.
:
' ~ PRIOR ART
- In the last two decades much interest has been paid to the10 development of monolithic devices for the controlled release of dmgs by various routes of administration.
'.., There are several types of polymers which have already been used as matrix for the release of drug. Thus, polymeric materials such as polyvinyl chloride, 1 15 polyethylene polyamides, ethylcellulose, silicone, poly(hydroxyethyl methacrylate)-J. PHEMA, other acrylic copolymers, polyvinylacetate-polyvinylchloride copolymers and other polymers were described as adequate matrix for tablet preparation (seefor example USP 3,087,860; USP 2,987,445; and Pharm. Acta Helv., 1981), 55, 174-182, Salomon et al.
The controlled or slow release of some drugs is of a high importance for biopharmaceutical applications. There are various systems of slow release, mostly based on diffusion-controlled release or swelling control release mechanisms.
- - Diffusion-controlled polymeric systems allow some prolongation of drug release but ~ 2 5 prov;de no real means of control since the release rate is not constant. ,,~, .'', ~
,.
:~"
.,;
..
. . ... :, . .: .
2~17~
Recently, many efforts have been devoted to the development of systems able to release the drug at a constant rate, in other words, following zero-order kinetics, such as described in S.T.P. Pharma 1986, 2, 3~-46 (Peppas et al.).
The approach called 'swelling-controlled' systems consists in glassy polymers into 5 which a water front penetrates at a constant rate. Behind this front, the polymer is . in a rubbery state. Provided the drug diffusion coefficient in the rubbery polymer is much higher than in the glassy polymer, a zero order release can be achieved to a certain degree. However, the delivery rate is constant only for a l;mited fraction of the release, usually around 60% of the total amount of contained drug, and l0 requires a low initial drug concentration.
Accordingly, it would be highly desirable to provi~e a slow release system following a zero-order kinetics, and allowing a controlled release of a drug : at a constant rate until all the drug is released, whatever the concentration of the 15 drug in the system is.
.' SUMMA~Y OF THE INVENTION
- In accordance with the present invention there is now provided a 20 solid slow release oral pharmaceutical dosage unit which comprises a solid dosage . unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product and a cross-linked polymer of amylose with a cross-linking .,, ~: agent selected from 2,3-dibromopropanol and epichlorohydrin, wherein the cross-linking of the polymer has been carried out with from about 0.1 to about 10 g of., :
25 cross-linking agent per 100 g of amylose.
: ;
;........................................................................... , .,~
~;
More particularly, there is provided a solid slow ; release oral pharmaceutical dosage unit consisting of a ~ compressed mixture of up to 60~ by weight of a dry powder of : a pharmaceutical product, with at least 40% by weight of a dry powder of amylose cross-linked with a cross-linking agent selected from the group consisting of epichlorohydrin and 2,3-dibromopropanol, wherein the cross-linking has been carried out with from about 0.1 to about 10 grams of cross-linking agent per 100 g of amylose.
- 10 In accordance with a preferred embodiment of the invention, most of the particles of the cross-linked polymer of amylose with a cross-linking agent have a size that . varies generally between about 25 and about 300 microns, but :~ can be as high as 700 microns.
` 15 Pr~ferably also, the pharmaceutical product is present in thP tablet in an amount of from about 10 to 60%
w/w .
DETAILED DESCRIPTION
Cross-linked amylose The cross-linking of amylose is well known in the literature. For example, the desired cross-linking can be carried out in the manner descri~ed in BIOCHIMIE 1978, ~g 535-537 (Mateescu) by reacting amylose with 25 epichlorohydrin in an alkaline medium. In the same manner, amylose can also be cross-linked with 2,3-dibromopropanol.
Essentially, the amylose is swollen in an alkaline medium such as sodium hydroxide and after homogeni~ation, an appropriate amount of cross-linking agent is added. After complete homogeni2ation, the reaction rnedium is trans~erred -. onto a water bath and heated for one hour at a temperature of ~om 40 to 45C
- and the temperature is then raised to from 60 to 75C for a further period of rom 1 lo 2 hours after which time the reaction is complete. The duration of heating can be varied as well as the amount of cross-linking agent used in the reaction.
.' '' ' ' , ,.
':; ~ '` '' ' ' ' :'' :. ' . , ' .
;'. . ~ ., ': ' .
":: , : , 20~177~
The resulting cross-linked gel is then sieved in wet form and the granules ranging from about 25 to about 700 ,um are collected for the preparation of the slow-release tablet of the present invention. The granules of 25 to about 300 ,um representing at least 50% of the granules are selected for use in accordance with 5 the present invention, A
The preferred cross-linked polymers of amylose with epichlorohydrin ` ~CLA) suitable for the purposes of the present invention are those where from about O.l to about 10 g of epichlorohydrin have been used to cross-linked 100 g of ~ 10 amylose. More preferred cross-linked polymers were obtained when from about 0.5 -~ to 7.5 g of epichlorohydrin per 100 g of amylose were used.
... .
..
'' In accordance with the present invention, it has been found that a polymer of amylose cross-linked with a cross-linking agent selected from 2,3-~;l 15 dibromopropanol and epichlorohydrin, wherein from about O.l to about lO g of cross-linking agent have been used to cross-linked 100 g of amylose, are surprisingly and unexpectedly suitable for the slow-release of a large variety of drugs asso~iated therewith. It has unexpectedly and surprisingly been found that the tablets prepared in accordarlce with the present invention are adapted to liberate the drug in a close 2 o to linear release for a period of from 1 l to 37 hours, or even more depending on the . amount of epichlorohydrin used to cross-linked amylose.
;
:~.
Preparation o~ tablets About 10 to 60% w/w of anhydrous theophylline was mixed with 2 5 cross-linked amylose (CLA) in a shaking mixer for a few minutes. Tablets weighing ' about 500 mg each were obtained by compression in a hydraulic press at more than ::.
: ~`
~ . .
,:
.".' -, . ~
~,.: ,:. . :
~ 2~ 774 . 0.15 T/cm2. Tablets of 1.26 cm diameter and thickness of about 2.9 to about 4.5 mm can be obtained depending on the applied pressure, but various geometry can also - be realized. Hardness tests have also shown that it is not dependent on the cross-linking degree.
In order to illustrate the advantages of the present invention, the release of theophylline from CLA tablets was selected as a model for kinetic studies of the release. Obviously other drugs could be incorporated in the CLA tablets of . the present invention and provide similar slow release characteristics, as long as 10 there is no interactions between the drug and the CLA.
'In vitro' dru~ ~elease from tablels Tablets were placed individually in lL distilled water at 37C in U.S.P. XX dissolution apparatus equipped with a rotating paddle (50 r.p.m.).
15 Theophylline release was followed spectrophotometrically at 254 nm (Pharmacia single path monitor UV-1) and continuously recorded; a closed loop system and a peristaltic pump at a flow rate of 10.0 mL/min, were used.
,., CLA is an interesting polymer for the preparation of controlled 2 0 release drug tablets. Advantages of this material include the easy manufacturing of . tablets, the possibility of maintaining controlled release even at a high drug concentration in the tablet, and the relative independence of release kinetics from .;- .
~. drug loading in certain limits. Furthermore, the CLA slow release matrix of the ~ ..
, present invention has high biocompatability, and total 'in vivo' biodegradability.
2 5 Also, tests have shown that the drug release kinetics are not in-fluenced at pH values ., :
`''' , _;S
"
:, . . . . .
, '~ ?~'.; ' ~
. " ~ , ~. .
~"' ' ' ' ' ' .' ' ' ' ' ~ ............................................ . .
- 2~177 .~
:, of from 1.5 to 11, which strongly suggest that the present release controlled system ;~ will be applicable in gastroenteric media.
The present invention will be more readily understood by referring 5 to the following examples which are given to illustrate the invention rather than limit its scope.
Cross-linkin~ of amvlose with epichlorohvdrin `' 10g of corn amylose are introduced, under agitation, in 35 mL SN
..,', NaOH, at Q-2C and homogenized at the same ternperature, on an ice bath, for about 30 min. Then, 0.1 g of epichlorohydrin are slowly added, and the homogenization continued, for another 30 min on the ice bath. After complete : homogenization, the recipient containing the reaction medium is transferred onto a water bath and heated for one hour at 40-45C, and then at 60-75 C for another 100 minutes, for completion of the reticulation reaction. During heating, 1-2 mL of water is added from time to time in order to avoid an advanced dehydration of the . reaction medium. After the reticulation is accomplished, the cross-linked amylose -:,'.
. gel is washed several times with distilled water for elimination of sodium hydroxide ....
~ excess, until a pH value of 6 of the distilled water is reached. The CLA gel is sieved . . .
.: 2 0 in wet form, retaining grains ranging between 25-75 ,um, and then dried by treatment .. and subsequent decantation with increasing acetone concentration. The whole , ...
procedure is carried out over a per;od of several hours. The last step consists of .
-~ ............ washing the resulting solid with pure acetone, directly on a Buchner filter, f~llowed .....
~ by drying at air overnight.
;:
: 2 5 , .
.:
::,J
,, !
.i . ~, . "
'.'`' ' `'`' ' ` ' , `'' ."' ` ' `
. ~` .
`
'. `' . . .
: 2~77~
The product prepared accs)rding to this Example will be referred to hereinafter as CLA-lØ
A similar cross-linked polymer was obtained by substitution of 2,3-5 dibromopropanol for epichlorohydrin.
` EXAMPLE 2 By proceeding in the same manner as in Example 1 and replacing the 0.1 g of epichlorohydrin by 0.4; 0.75; 1.2 and 2.0 g, there is obtained corresponding ~; 10cross linked products hereinafter identified as CLA-4.0, CLA-75, CLA-12, and CLA-20.
; EXAMPLE 3 Preparation of Tablets.
Anhydrous theophylline reagent grade (Baker) is mixed (10% w/w) 15 with cross-linked amylose in Turbula shaking mixer for about 10 min. 'rablets . weighing about S00 mg each are obtained by compression in Carver hydraulic press at more than 2.4 T/cm~, with a 1.26 cm diameter and thickness of 2.9 mm. The same procedure can be applied for different amounts of theophylline in the tablets.
For example, tablets containing 10, 20, 30, 40, S0 and 60% wtw of theophylline were 2 0 prepared.
. ~ EXAMPLE 4 ..'In vitro' dru~ release results. EqllilibriNm swellin~
-~, Equilibrium swelling of various types of Cl A polymeric powder, CLA
: .
. drug free tables and CLA containing 10% theophylline tablets are measured in water :~ 2 5and various aqueous solvents at room temperature.
:.
~`:
~.
,~ "~
,: ,...
.... . . .
. .
~ 29~77~
The tablets or the equivalent mass of 500 mg of CLA powder are ;. placed in a 50 mL graduate cylinder to which 50 mL water or aqueous solvents are added. After 96 hours, the equilibrium swelling volume was read directly. The swelling is expressed as swollen volume per weight unit of initial dry material 5 (mL/g). The swelling volume of the powders in water varied from 12 to 42 mL/g.
`:,.'' - Analvsis oï theophvlline release from CLA tablets .
` Theophylline release data are analyzed using the equation proposed , -: 10 by Peppas in Pharm. Acta Helv. 1985, 60, 110~
` Mt - The amount released at t Mt M~" - Total amount released -- = ktn where t - Time M0 k - Kinetic constant n - Characterizes the release mechanism as summarized in table I
Table I: Analysis oï dif~usional release mechanism . ~
'~ Diffusional release Overall solute release Time dependance of solute ;., exponent (n) mechanism release rate (dMt/dt) -::
:
.` 25 n=0.5 Fickian diffusion t-05 0.5 < n < 1.0 Anomalous diffusion tn-l : :.
n = 1 Case II transport zero-order (t) . 3 0 `'. D> 1 Super case II transport tn-:...
In the above Table I, the Fickian diffusion is controlled by Fick's laws, 3 5 and the release is in a hyperbolic function upon the time, and linear iD function of ;`~ t 1/2. In the anomalous diffusion, tbe release curve upon the time is somewhat ` j between the hyperbolic and linear dependency. In Case II transport, the release , :;
..:
~,...
:,.
~' ~' ' ' `, ` ' , ' , ` ' ' .. , 2~1774 , 9 curve is linear in function of the time, whereas Supercase II transport is for an exponential function of the release upon the time.
., Table II shows examples of theophylline release from tablets initially . :. 5containing 10 to 60% theophylline in CLA. Analysis of solute release data for CLA-1.0, CLA-4.0 and CLA-7.5 between to (to = initial time) and t 90 (corresponding to 90% of total theophylline release) are also presented in Table II.
Table II: Kinetics parameters oî 90% release o~ the initial 10theophylline amount ¦ ~pe of gel Drug Release Kinetic Kinetic content % time(hours) parameter parameter :~JM, = 90;- k* n*
Amylose 10 1.2 0.785 0.876 -.. CLA-1.0 10 __ 37.0 0.129 0.537 .1 CLA-1.0 S0 _ 32.0 0.096 0.634 CLA-1.0 60 24.~) 0.013 O.SS1 -:
20CLA-4.0 10 25.0 _ 0.126 0.634 CLA-4.0 40 24.0 0.162 _ 0.531 ,, ,.,$, CLA-4.0 S0 13.0 0.283_ 0.423 .` CLA-7.5 10 _ 11.5 0.182 _ 0.662 CLA-7.5 20 11.5 0.161 0.702 .. ~ 2 5 CLA-7.5 30 7.0 n.d. n.d.
S CLA-12.0 10 1.3 0.760 0.890 CLA-20.0 _ 10 0.7 1.330 1.~10 .,.~" ~....... _ __ _ - . 3 0 * Kinetic parameters from Peppas ecluation .. n.d. = No representative ....i,~
' :, ,. :
2~7~
These data are obtained wh~n release of the theophylline occurs from all faces of the tablee. Most values of n are ranging between 0.5 and 1, which is indicative of an anomalous solute release mechanism, as illustrated in Table I.
Indeed, the theophylline release from the CLA tablets of the present invention follow a generally close to linear dependency upon time, which is a characteristic of anomalous release type. Since there is no glassy/rubbery transition in the polymer used in accordance with the present invention, the deviation from a fickian behaviour cannot be explained by the 'swelling control' release mechanism as described in S.T.P. Pharma, (supra).
~'' 10 The theophylline powder is mixed with polymeric granules prior to compression. Thus the tablet consists in an agglomerate of polymeric granules surrounded by theophylline. This is completely different from the 'swelling control ., - ~ - system' in which the drug is molecularly dispersed into a glassy polymer which turns . .
- ~ 15 into a rubbery one upon solvent penetration. When water penetrates into the tablet, the polymer hydrates and swells. CLA-1.0 has a low cross-linking degree and a small .,.
number of three-dimensional transversal glycerine bridges introduced by the cross-- linking. As a consequence, it is assumed that an irnportant number of hydrogen `. bounds can be created between neighbouring polymeric chains following the . . .
` 2 0 compression. The slow theophylline release from CLA-l.0 tablets could therefore - be attributed to a slow water penetration due to the presence of numerous :;
~`. intragranular hydrogens bonds. At higher cross-linking ratios, the higher density of . glyceric bridges of a total length of 8.6~ A (resulting from epichlorohydrin treatment) between adjacent amylose chains may prevent the network frorn coming -:.
2 5 near the distance necessary to form hydrogen bonds. Typically, this distance is about .. ..
` 5.6A.
`''`
- .
. . ' . ' , ' ' ~,........................................... ..
2~177 :-.
On the other hand, following the introduction into water, the tablets made with CLA having a higher reticulation degree, e.g. CLA-12 and CLA-20, were . totally disaggregated over a period of approximately 90 minutes. Consequently, theophylline release was faster and closer to linearity, with k= 0.76 and n = 0.890 for CLA-12 and with k= 1.33 and n= 1.21 for CLA-20 respectively (Table II).
It is interesting to note that small changes in the reticulation degree, for instance between CLA-7.5 and CLA-12, with swelling volumes of powders of 17.2 and 14.4 mL/g respectively, produce important differences in release kinetics, i.e.
10 the release time decreased from 15 to 2 hrs. However, differences of the same order in the reticulation degree of CLA-12 and CLA-20, with swelling volumes of powders of 14.4 and 12.0 mL/g respectively, have no significant effect on the release kinetics, that is about 2 hours in both cases. These data confirm the importance of ~^
. the hydrogen associations in the case of CLA-1.0, CLA-4.0 and CLA-7.5 tablets.
. 15 Accordingly, one can assume that at higher cross-linking degree of ......
amylose, fewer hydrogen bonds are formed, thus not allowing good cohesion of the !,`; tablet. Upon swelling, individual polymeric granules separate and the drug is .
~ released too ~ast.
:
-~ 20 . It is assumed that in the case of CLA-1.0, CI.A-4.0 and CLA-7.5, -:
hydrogen bonds are formed within polymeric granules as a result of the compression ` effort, ensuring good cohesion in the tablets, even under swollen state. This -; cohesion plays an important role in the control of the water penetration rate and in . :.
~ 25 preventing the tablet from a rapid disintegration.
.~
' , , , , :; :
20~1 774 It is therefore assumed that the drug release is controlled partly by the water penetration forming new water-amylose hydrogen associations, which can even replace the amylose-amylose interchains hydrogen bonds. This behaviour plays .~
a role in the deviation from the direct dependency Df fickian diffusion mechanism.
5 The presence of strong intragranular hydrogen bonds in the CLA-l.0, CLA-4.0 and CLA-7.5 tablets are confirmed by measuring equilibrium swelling of CLA in tablets and powder, using water and 8 M urea respectively, to demonstrate the formation of interchain hydrogen bonds. Table III iUustrates the equilibrium swelling of various cross~linked amylose.
.
.~
. .
., .:
. . .
;
~.
.' . ~
; .
. .
~.-. .
: ,.
...
-., .
.
:
.j :` ~
:'.
'`,`.
.... . . . .
''.': ` . .
'`:- ~ ` ' ' ' -`` 20~i~7~
~: -- 13 --. .
~' Table III: Equilibrum swelling oï cross~ ked amylose (Swollen gel ~olume/initial dry polymer weight) 5¦ Material Equilibrum Equilibrum Ratio swe~i g ¦
swelling in water swelling (8 M (8M urea/water) (mL/g) urea) (mL/g) l ~ 11 ¦ CLA-1.0 Powder 42.0 n.d. n.d CLA-1.0 Tablet 2.0 n.d. n.d Ratio* P/T 21.0 _ 10CLA-4.0 Powder 22.0 34.0 1.5 ;: CLA-4.0 Tablet 5.0 26.0 5.2 Ratio* P/T 4 4 .
CLA-7.5 Powder 17.2 23.0 1.3 CLA-7.5 Tablet 5.0 24.0 4.8 15Ratio* P/T 3.4 CLA-12 Powder 14.4 24.0 1.6 .. CLA-12 Tablet 12.4 24.0 1.9 Ratio* P/T 1.16 CLA-20 Powder 12.0 24.0 2.0 2 0CLA-20 Tablet 10.4 24.0 2.3 .~; Ratio~ P/T 1.15 _ _ .,. . .
.,.
;~
n.d.=No deposition of the gel .~ 25 Ratio* P/T=Swollen volume of CLA powder . Swollen volume of CLA Tablet :
`~ As shown in Table III, the swelling volumes of all CLA tablets and ;
powder were higher in 8M urea than in water. For CLA-1.0 and CLA-4(), the ratio :.
3 0 P/T was higher than for all other CLA types, supporting the hypothesis of interchain hydrogen association following the compression. For each cross-linking degree, ~::
equilibrium swelling in water was more important for powders than for tablets, ., ~ .
'' , . .: ` ' .:
,.,', ~ ' '' ' ,: :' `- 2~177~
` probably because of the new intragranular hydrogen bonds created by compression.
Thus, the ratio of swelling in 8M urea/water was significantly more pronounced in the case of lower reticulated CLA tablets which develops more intragranular hydrogen bonds than amylose having a higher reticulation degree. For instance, the values of the ratio swelling were 5.2 for CLA-4.0 tablets, and then decreasing to 1.9 for CLA-12 and to 2.3 for CLA-20 tablets. Therefore, these results are consistent with the hypothesis that tablets of lower cross-linking of amylose show good cohesion because of strong intragranular hydrogen bonds.
.
`. 10 Since granullometrics and compression forces were also similar, tablets should present no significant difference in consistence. It is therefore.. . unlikely that the observed difference in theophylline release kinetics could result ;. from the effect of porosity on water penetration kinetics. Furthermore, the specific ' volume (42 mL/g) of dried CLA-l.0 powder was the highest, while the swelling of 15 CLA-l.0 tablets was the lowest, and the theophylline release from this type of . product was the slowest. Therefore, these results confirm that hydrogen associations :"',.
~; are irnplied in the release control, rather than the porosity of CLA.
-. i The influence of theophylline content in tablets on the drug release ... ` 2 0 kinetics was also studied. In all cases, the yield of release was more than 95% in various kinetic conditions, between to and t90 f total theophylline release, depending ` on the reticulation degree and the drug content of the tablet. The release kinetics :~ were partially similar at about 10-20% of theophylline for CLA-7.5; 10 to 40% of theophylline for CLA-4.0 and 10-50% of theophylline for CLA-1Ø This observation : 2 5 is consistent with the fact that these tablets are neither behaving like conventional hydrophillic matrix nor like 'swelling-controlled' systems. Incleed, in this last case, :-~:
~,,.
, ...?
.~ . , ~ 20~77~
doubling the dru~ concentration would have modified the release kinetics more extensively. At the maximum capacities of drug content in the tablets, the release was much faster and showed irregular kinetics (Table II). Tablets of CLA-1.0, CLA-4.0 and CLA 7.5 containing a drug concentration higher than the m~imum capacity 5 were also partially disaggregated. The high amount of drug between polymeric granules probably caused insufficient cohesion, therefore leading to partial desaggregation.
.~'.
Finally, the release of theophylline from pure amylose tablets was studied. The release is fast (1-2 hours when k~0.785, n=0.876), accompanied by ;~ erosion of the tablet. Furthermore, the release of theophylline from non cross-`- linked amylose tablets is quite similar to the release from CLA-12 and CLA-20 .:~. tablets. This fast release in the case of non cross-linked amylose demonstrates the irnportance of the particular three-dimensional structure, in which the interchain 15 hydrogen bonds play a major role in the drug release rate.
;''''' From this dependence bet~,veen the release time and the reticulation :;: degree, evidence is given that for the low reticulation degrees, between 0 and 10%, the interchain hydrogen bonding is maximal, and seems to participate in the control 2 O of the theophylline release.
',.' ::.
.
.. .. ..
- 10 In accordance with a preferred embodiment of the invention, most of the particles of the cross-linked polymer of amylose with a cross-linking agent have a size that . varies generally between about 25 and about 300 microns, but :~ can be as high as 700 microns.
` 15 Pr~ferably also, the pharmaceutical product is present in thP tablet in an amount of from about 10 to 60%
w/w .
DETAILED DESCRIPTION
Cross-linked amylose The cross-linking of amylose is well known in the literature. For example, the desired cross-linking can be carried out in the manner descri~ed in BIOCHIMIE 1978, ~g 535-537 (Mateescu) by reacting amylose with 25 epichlorohydrin in an alkaline medium. In the same manner, amylose can also be cross-linked with 2,3-dibromopropanol.
Essentially, the amylose is swollen in an alkaline medium such as sodium hydroxide and after homogeni~ation, an appropriate amount of cross-linking agent is added. After complete homogeni2ation, the reaction rnedium is trans~erred -. onto a water bath and heated for one hour at a temperature of ~om 40 to 45C
- and the temperature is then raised to from 60 to 75C for a further period of rom 1 lo 2 hours after which time the reaction is complete. The duration of heating can be varied as well as the amount of cross-linking agent used in the reaction.
.' '' ' ' , ,.
':; ~ '` '' ' ' ' :'' :. ' . , ' .
;'. . ~ ., ': ' .
":: , : , 20~177~
The resulting cross-linked gel is then sieved in wet form and the granules ranging from about 25 to about 700 ,um are collected for the preparation of the slow-release tablet of the present invention. The granules of 25 to about 300 ,um representing at least 50% of the granules are selected for use in accordance with 5 the present invention, A
The preferred cross-linked polymers of amylose with epichlorohydrin ` ~CLA) suitable for the purposes of the present invention are those where from about O.l to about 10 g of epichlorohydrin have been used to cross-linked 100 g of ~ 10 amylose. More preferred cross-linked polymers were obtained when from about 0.5 -~ to 7.5 g of epichlorohydrin per 100 g of amylose were used.
... .
..
'' In accordance with the present invention, it has been found that a polymer of amylose cross-linked with a cross-linking agent selected from 2,3-~;l 15 dibromopropanol and epichlorohydrin, wherein from about O.l to about lO g of cross-linking agent have been used to cross-linked 100 g of amylose, are surprisingly and unexpectedly suitable for the slow-release of a large variety of drugs asso~iated therewith. It has unexpectedly and surprisingly been found that the tablets prepared in accordarlce with the present invention are adapted to liberate the drug in a close 2 o to linear release for a period of from 1 l to 37 hours, or even more depending on the . amount of epichlorohydrin used to cross-linked amylose.
;
:~.
Preparation o~ tablets About 10 to 60% w/w of anhydrous theophylline was mixed with 2 5 cross-linked amylose (CLA) in a shaking mixer for a few minutes. Tablets weighing ' about 500 mg each were obtained by compression in a hydraulic press at more than ::.
: ~`
~ . .
,:
.".' -, . ~
~,.: ,:. . :
~ 2~ 774 . 0.15 T/cm2. Tablets of 1.26 cm diameter and thickness of about 2.9 to about 4.5 mm can be obtained depending on the applied pressure, but various geometry can also - be realized. Hardness tests have also shown that it is not dependent on the cross-linking degree.
In order to illustrate the advantages of the present invention, the release of theophylline from CLA tablets was selected as a model for kinetic studies of the release. Obviously other drugs could be incorporated in the CLA tablets of . the present invention and provide similar slow release characteristics, as long as 10 there is no interactions between the drug and the CLA.
'In vitro' dru~ ~elease from tablels Tablets were placed individually in lL distilled water at 37C in U.S.P. XX dissolution apparatus equipped with a rotating paddle (50 r.p.m.).
15 Theophylline release was followed spectrophotometrically at 254 nm (Pharmacia single path monitor UV-1) and continuously recorded; a closed loop system and a peristaltic pump at a flow rate of 10.0 mL/min, were used.
,., CLA is an interesting polymer for the preparation of controlled 2 0 release drug tablets. Advantages of this material include the easy manufacturing of . tablets, the possibility of maintaining controlled release even at a high drug concentration in the tablet, and the relative independence of release kinetics from .;- .
~. drug loading in certain limits. Furthermore, the CLA slow release matrix of the ~ ..
, present invention has high biocompatability, and total 'in vivo' biodegradability.
2 5 Also, tests have shown that the drug release kinetics are not in-fluenced at pH values ., :
`''' , _;S
"
:, . . . . .
, '~ ?~'.; ' ~
. " ~ , ~. .
~"' ' ' ' ' ' .' ' ' ' ' ~ ............................................ . .
- 2~177 .~
:, of from 1.5 to 11, which strongly suggest that the present release controlled system ;~ will be applicable in gastroenteric media.
The present invention will be more readily understood by referring 5 to the following examples which are given to illustrate the invention rather than limit its scope.
Cross-linkin~ of amvlose with epichlorohvdrin `' 10g of corn amylose are introduced, under agitation, in 35 mL SN
..,', NaOH, at Q-2C and homogenized at the same ternperature, on an ice bath, for about 30 min. Then, 0.1 g of epichlorohydrin are slowly added, and the homogenization continued, for another 30 min on the ice bath. After complete : homogenization, the recipient containing the reaction medium is transferred onto a water bath and heated for one hour at 40-45C, and then at 60-75 C for another 100 minutes, for completion of the reticulation reaction. During heating, 1-2 mL of water is added from time to time in order to avoid an advanced dehydration of the . reaction medium. After the reticulation is accomplished, the cross-linked amylose -:,'.
. gel is washed several times with distilled water for elimination of sodium hydroxide ....
~ excess, until a pH value of 6 of the distilled water is reached. The CLA gel is sieved . . .
.: 2 0 in wet form, retaining grains ranging between 25-75 ,um, and then dried by treatment .. and subsequent decantation with increasing acetone concentration. The whole , ...
procedure is carried out over a per;od of several hours. The last step consists of .
-~ ............ washing the resulting solid with pure acetone, directly on a Buchner filter, f~llowed .....
~ by drying at air overnight.
;:
: 2 5 , .
.:
::,J
,, !
.i . ~, . "
'.'`' ' `'`' ' ` ' , `'' ."' ` ' `
. ~` .
`
'. `' . . .
: 2~77~
The product prepared accs)rding to this Example will be referred to hereinafter as CLA-lØ
A similar cross-linked polymer was obtained by substitution of 2,3-5 dibromopropanol for epichlorohydrin.
` EXAMPLE 2 By proceeding in the same manner as in Example 1 and replacing the 0.1 g of epichlorohydrin by 0.4; 0.75; 1.2 and 2.0 g, there is obtained corresponding ~; 10cross linked products hereinafter identified as CLA-4.0, CLA-75, CLA-12, and CLA-20.
; EXAMPLE 3 Preparation of Tablets.
Anhydrous theophylline reagent grade (Baker) is mixed (10% w/w) 15 with cross-linked amylose in Turbula shaking mixer for about 10 min. 'rablets . weighing about S00 mg each are obtained by compression in Carver hydraulic press at more than 2.4 T/cm~, with a 1.26 cm diameter and thickness of 2.9 mm. The same procedure can be applied for different amounts of theophylline in the tablets.
For example, tablets containing 10, 20, 30, 40, S0 and 60% wtw of theophylline were 2 0 prepared.
. ~ EXAMPLE 4 ..'In vitro' dru~ release results. EqllilibriNm swellin~
-~, Equilibrium swelling of various types of Cl A polymeric powder, CLA
: .
. drug free tables and CLA containing 10% theophylline tablets are measured in water :~ 2 5and various aqueous solvents at room temperature.
:.
~`:
~.
,~ "~
,: ,...
.... . . .
. .
~ 29~77~
The tablets or the equivalent mass of 500 mg of CLA powder are ;. placed in a 50 mL graduate cylinder to which 50 mL water or aqueous solvents are added. After 96 hours, the equilibrium swelling volume was read directly. The swelling is expressed as swollen volume per weight unit of initial dry material 5 (mL/g). The swelling volume of the powders in water varied from 12 to 42 mL/g.
`:,.'' - Analvsis oï theophvlline release from CLA tablets .
` Theophylline release data are analyzed using the equation proposed , -: 10 by Peppas in Pharm. Acta Helv. 1985, 60, 110~
` Mt - The amount released at t Mt M~" - Total amount released -- = ktn where t - Time M0 k - Kinetic constant n - Characterizes the release mechanism as summarized in table I
Table I: Analysis oï dif~usional release mechanism . ~
'~ Diffusional release Overall solute release Time dependance of solute ;., exponent (n) mechanism release rate (dMt/dt) -::
:
.` 25 n=0.5 Fickian diffusion t-05 0.5 < n < 1.0 Anomalous diffusion tn-l : :.
n = 1 Case II transport zero-order (t) . 3 0 `'. D> 1 Super case II transport tn-:...
In the above Table I, the Fickian diffusion is controlled by Fick's laws, 3 5 and the release is in a hyperbolic function upon the time, and linear iD function of ;`~ t 1/2. In the anomalous diffusion, tbe release curve upon the time is somewhat ` j between the hyperbolic and linear dependency. In Case II transport, the release , :;
..:
~,...
:,.
~' ~' ' ' `, ` ' , ' , ` ' ' .. , 2~1774 , 9 curve is linear in function of the time, whereas Supercase II transport is for an exponential function of the release upon the time.
., Table II shows examples of theophylline release from tablets initially . :. 5containing 10 to 60% theophylline in CLA. Analysis of solute release data for CLA-1.0, CLA-4.0 and CLA-7.5 between to (to = initial time) and t 90 (corresponding to 90% of total theophylline release) are also presented in Table II.
Table II: Kinetics parameters oî 90% release o~ the initial 10theophylline amount ¦ ~pe of gel Drug Release Kinetic Kinetic content % time(hours) parameter parameter :~JM, = 90;- k* n*
Amylose 10 1.2 0.785 0.876 -.. CLA-1.0 10 __ 37.0 0.129 0.537 .1 CLA-1.0 S0 _ 32.0 0.096 0.634 CLA-1.0 60 24.~) 0.013 O.SS1 -:
20CLA-4.0 10 25.0 _ 0.126 0.634 CLA-4.0 40 24.0 0.162 _ 0.531 ,, ,.,$, CLA-4.0 S0 13.0 0.283_ 0.423 .` CLA-7.5 10 _ 11.5 0.182 _ 0.662 CLA-7.5 20 11.5 0.161 0.702 .. ~ 2 5 CLA-7.5 30 7.0 n.d. n.d.
S CLA-12.0 10 1.3 0.760 0.890 CLA-20.0 _ 10 0.7 1.330 1.~10 .,.~" ~....... _ __ _ - . 3 0 * Kinetic parameters from Peppas ecluation .. n.d. = No representative ....i,~
' :, ,. :
2~7~
These data are obtained wh~n release of the theophylline occurs from all faces of the tablee. Most values of n are ranging between 0.5 and 1, which is indicative of an anomalous solute release mechanism, as illustrated in Table I.
Indeed, the theophylline release from the CLA tablets of the present invention follow a generally close to linear dependency upon time, which is a characteristic of anomalous release type. Since there is no glassy/rubbery transition in the polymer used in accordance with the present invention, the deviation from a fickian behaviour cannot be explained by the 'swelling control' release mechanism as described in S.T.P. Pharma, (supra).
~'' 10 The theophylline powder is mixed with polymeric granules prior to compression. Thus the tablet consists in an agglomerate of polymeric granules surrounded by theophylline. This is completely different from the 'swelling control ., - ~ - system' in which the drug is molecularly dispersed into a glassy polymer which turns . .
- ~ 15 into a rubbery one upon solvent penetration. When water penetrates into the tablet, the polymer hydrates and swells. CLA-1.0 has a low cross-linking degree and a small .,.
number of three-dimensional transversal glycerine bridges introduced by the cross-- linking. As a consequence, it is assumed that an irnportant number of hydrogen `. bounds can be created between neighbouring polymeric chains following the . . .
` 2 0 compression. The slow theophylline release from CLA-l.0 tablets could therefore - be attributed to a slow water penetration due to the presence of numerous :;
~`. intragranular hydrogens bonds. At higher cross-linking ratios, the higher density of . glyceric bridges of a total length of 8.6~ A (resulting from epichlorohydrin treatment) between adjacent amylose chains may prevent the network frorn coming -:.
2 5 near the distance necessary to form hydrogen bonds. Typically, this distance is about .. ..
` 5.6A.
`''`
- .
. . ' . ' , ' ' ~,........................................... ..
2~177 :-.
On the other hand, following the introduction into water, the tablets made with CLA having a higher reticulation degree, e.g. CLA-12 and CLA-20, were . totally disaggregated over a period of approximately 90 minutes. Consequently, theophylline release was faster and closer to linearity, with k= 0.76 and n = 0.890 for CLA-12 and with k= 1.33 and n= 1.21 for CLA-20 respectively (Table II).
It is interesting to note that small changes in the reticulation degree, for instance between CLA-7.5 and CLA-12, with swelling volumes of powders of 17.2 and 14.4 mL/g respectively, produce important differences in release kinetics, i.e.
10 the release time decreased from 15 to 2 hrs. However, differences of the same order in the reticulation degree of CLA-12 and CLA-20, with swelling volumes of powders of 14.4 and 12.0 mL/g respectively, have no significant effect on the release kinetics, that is about 2 hours in both cases. These data confirm the importance of ~^
. the hydrogen associations in the case of CLA-1.0, CLA-4.0 and CLA-7.5 tablets.
. 15 Accordingly, one can assume that at higher cross-linking degree of ......
amylose, fewer hydrogen bonds are formed, thus not allowing good cohesion of the !,`; tablet. Upon swelling, individual polymeric granules separate and the drug is .
~ released too ~ast.
:
-~ 20 . It is assumed that in the case of CLA-1.0, CI.A-4.0 and CLA-7.5, -:
hydrogen bonds are formed within polymeric granules as a result of the compression ` effort, ensuring good cohesion in the tablets, even under swollen state. This -; cohesion plays an important role in the control of the water penetration rate and in . :.
~ 25 preventing the tablet from a rapid disintegration.
.~
' , , , , :; :
20~1 774 It is therefore assumed that the drug release is controlled partly by the water penetration forming new water-amylose hydrogen associations, which can even replace the amylose-amylose interchains hydrogen bonds. This behaviour plays .~
a role in the deviation from the direct dependency Df fickian diffusion mechanism.
5 The presence of strong intragranular hydrogen bonds in the CLA-l.0, CLA-4.0 and CLA-7.5 tablets are confirmed by measuring equilibrium swelling of CLA in tablets and powder, using water and 8 M urea respectively, to demonstrate the formation of interchain hydrogen bonds. Table III iUustrates the equilibrium swelling of various cross~linked amylose.
.
.~
. .
., .:
. . .
;
~.
.' . ~
; .
. .
~.-. .
: ,.
...
-., .
.
:
.j :` ~
:'.
'`,`.
.... . . . .
''.': ` . .
'`:- ~ ` ' ' ' -`` 20~i~7~
~: -- 13 --. .
~' Table III: Equilibrum swelling oï cross~ ked amylose (Swollen gel ~olume/initial dry polymer weight) 5¦ Material Equilibrum Equilibrum Ratio swe~i g ¦
swelling in water swelling (8 M (8M urea/water) (mL/g) urea) (mL/g) l ~ 11 ¦ CLA-1.0 Powder 42.0 n.d. n.d CLA-1.0 Tablet 2.0 n.d. n.d Ratio* P/T 21.0 _ 10CLA-4.0 Powder 22.0 34.0 1.5 ;: CLA-4.0 Tablet 5.0 26.0 5.2 Ratio* P/T 4 4 .
CLA-7.5 Powder 17.2 23.0 1.3 CLA-7.5 Tablet 5.0 24.0 4.8 15Ratio* P/T 3.4 CLA-12 Powder 14.4 24.0 1.6 .. CLA-12 Tablet 12.4 24.0 1.9 Ratio* P/T 1.16 CLA-20 Powder 12.0 24.0 2.0 2 0CLA-20 Tablet 10.4 24.0 2.3 .~; Ratio~ P/T 1.15 _ _ .,. . .
.,.
;~
n.d.=No deposition of the gel .~ 25 Ratio* P/T=Swollen volume of CLA powder . Swollen volume of CLA Tablet :
`~ As shown in Table III, the swelling volumes of all CLA tablets and ;
powder were higher in 8M urea than in water. For CLA-1.0 and CLA-4(), the ratio :.
3 0 P/T was higher than for all other CLA types, supporting the hypothesis of interchain hydrogen association following the compression. For each cross-linking degree, ~::
equilibrium swelling in water was more important for powders than for tablets, ., ~ .
'' , . .: ` ' .:
,.,', ~ ' '' ' ,: :' `- 2~177~
` probably because of the new intragranular hydrogen bonds created by compression.
Thus, the ratio of swelling in 8M urea/water was significantly more pronounced in the case of lower reticulated CLA tablets which develops more intragranular hydrogen bonds than amylose having a higher reticulation degree. For instance, the values of the ratio swelling were 5.2 for CLA-4.0 tablets, and then decreasing to 1.9 for CLA-12 and to 2.3 for CLA-20 tablets. Therefore, these results are consistent with the hypothesis that tablets of lower cross-linking of amylose show good cohesion because of strong intragranular hydrogen bonds.
.
`. 10 Since granullometrics and compression forces were also similar, tablets should present no significant difference in consistence. It is therefore.. . unlikely that the observed difference in theophylline release kinetics could result ;. from the effect of porosity on water penetration kinetics. Furthermore, the specific ' volume (42 mL/g) of dried CLA-l.0 powder was the highest, while the swelling of 15 CLA-l.0 tablets was the lowest, and the theophylline release from this type of . product was the slowest. Therefore, these results confirm that hydrogen associations :"',.
~; are irnplied in the release control, rather than the porosity of CLA.
-. i The influence of theophylline content in tablets on the drug release ... ` 2 0 kinetics was also studied. In all cases, the yield of release was more than 95% in various kinetic conditions, between to and t90 f total theophylline release, depending ` on the reticulation degree and the drug content of the tablet. The release kinetics :~ were partially similar at about 10-20% of theophylline for CLA-7.5; 10 to 40% of theophylline for CLA-4.0 and 10-50% of theophylline for CLA-1Ø This observation : 2 5 is consistent with the fact that these tablets are neither behaving like conventional hydrophillic matrix nor like 'swelling-controlled' systems. Incleed, in this last case, :-~:
~,,.
, ...?
.~ . , ~ 20~77~
doubling the dru~ concentration would have modified the release kinetics more extensively. At the maximum capacities of drug content in the tablets, the release was much faster and showed irregular kinetics (Table II). Tablets of CLA-1.0, CLA-4.0 and CLA 7.5 containing a drug concentration higher than the m~imum capacity 5 were also partially disaggregated. The high amount of drug between polymeric granules probably caused insufficient cohesion, therefore leading to partial desaggregation.
.~'.
Finally, the release of theophylline from pure amylose tablets was studied. The release is fast (1-2 hours when k~0.785, n=0.876), accompanied by ;~ erosion of the tablet. Furthermore, the release of theophylline from non cross-`- linked amylose tablets is quite similar to the release from CLA-12 and CLA-20 .:~. tablets. This fast release in the case of non cross-linked amylose demonstrates the irnportance of the particular three-dimensional structure, in which the interchain 15 hydrogen bonds play a major role in the drug release rate.
;''''' From this dependence bet~,veen the release time and the reticulation :;: degree, evidence is given that for the low reticulation degrees, between 0 and 10%, the interchain hydrogen bonding is maximal, and seems to participate in the control 2 O of the theophylline release.
',.' ::.
.
.. .. ..
Claims (8)
1. A solid slow release oral pharmaceutical dosage unit consisting of a compressed mixture of up to 60%
by weight of a dry powder of a pharmaceutical product, with at least 40% by weight of a dry powder of amylose cross-linked with a cross-linking agent selected from the group consisting of epichlorohydrin and wherein the cross-linking has been carried out with from about 0.1 to about 10 grams of cross-linking agent per loo g of amylose.
by weight of a dry powder of a pharmaceutical product, with at least 40% by weight of a dry powder of amylose cross-linked with a cross-linking agent selected from the group consisting of epichlorohydrin and wherein the cross-linking has been carried out with from about 0.1 to about 10 grams of cross-linking agent per loo g of amylose.
2. The oral pharmaceutical dosage unit of claim 1, wherein the cross-linking agent is epichlorohydrin.
3. The oral pharmaceutical dosage unit of claim 2, wherein the cross-linking is carried out with from about 0.5 to about 7.5 g of epichlorohydrin per 100 g of amylose.
4. The oral pharmaceutical dosage unit of claim 1, 2 or 3, wherein at least 50% of said cross-linked amylose has a particle size of from about 25 to about 700 microns.
5. The oral pharmaceutical dosage unit of claim 1, 2 or 3, wherein said unit is in the form of a tablet.
6. The oral pharmaceutical dosage unit of claim 5, wherein said tablet has been formed by compression of said powders under a compression of at least 0.15 T/cm2.
7. The oral pharmaceutical dosage unit of claim 7, wherein said unit is in the form of a tablet.
8. The oral pharmaceutical dosage unit of claim 7, wherein said tablet has been formed by compression of said powders under a compression of at least 0.15 T/cm2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61865090A | 1990-11-27 | 1990-11-27 | |
| US618,650 | 1990-11-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2041774A1 CA2041774A1 (en) | 1992-05-28 |
| CA2041774C true CA2041774C (en) | 1994-04-19 |
Family
ID=24478563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002041774A Expired - Lifetime CA2041774C (en) | 1990-11-27 | 1991-05-03 | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US5456921A (en) |
| CA (1) | CA2041774C (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5603956A (en) * | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
| NL9201195A (en) * | 1992-07-03 | 1994-02-01 | Tno | PREPARATION FOR THE REGULATED DELIVERY OF AN ACTIVE SUBSTANCE AND METHOD FOR PREPARING SUCH A PREPARATION. |
| US5616343A (en) * | 1993-03-25 | 1997-04-01 | Labopharm, Inc. | Cross-linked amylose as a binder/disintegrant in tablets |
| IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| CA2173818A1 (en) * | 1996-04-10 | 1997-10-11 | Francois Chouinard | Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose |
| US5753287A (en) * | 1996-09-24 | 1998-05-19 | National Starch And Chemical Investment Holding Corporation | Flavored popping corn with low or no fat |
| DE19640062B4 (en) * | 1996-09-28 | 2006-04-27 | Lts Lohmann Therapie-Systeme Ag | Oral preparation comprising in a matrix swellable in an aqueous medium at least one pharmaceutical active substance |
| US5879707A (en) * | 1996-10-30 | 1999-03-09 | Universite De Montreal | Substituted amylose as a matrix for sustained drug release |
| GB2334886B (en) * | 1996-12-18 | 2000-08-23 | Bimeda Res Dev Ltd | Antiinfective free intramammary veterinary composition |
| US5807575A (en) * | 1997-02-14 | 1998-09-15 | Rougier Inc. | Manufacture of cross-linked amylose useful as a excipient for control release of active compounds |
| AU7501398A (en) * | 1997-05-21 | 1998-12-11 | Warner-Lambert Company | Non-sedating acrivastine preparation |
| CA2217238C (en) * | 1997-10-24 | 2005-09-20 | Louis Cartilier | Cross-linked cellulose as a tablet excipient |
| US6284273B1 (en) * | 1998-02-24 | 2001-09-04 | Vincent Lenaerts | Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds |
| US6660303B2 (en) * | 1999-12-06 | 2003-12-09 | Edward Mendell & Co. | Pharmaceutical superdisintegrant |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| JP2004513975A (en) | 2000-12-05 | 2004-05-13 | マクグレゴール アレキサンダー | Hydrostatic delivery system for controlled release of active substance |
| WO2002088331A1 (en) * | 2001-05-01 | 2002-11-07 | Universite Du Quebec A Montreal | Tridimensional biocompatible support structure for bioartificial organs and uses thereof |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| US20080286253A1 (en) * | 2004-02-09 | 2008-11-20 | Transfert Plus Societe En Commandite | Composition Comprising Polymeric Material And Uses Thereof |
| CA2586611A1 (en) | 2004-11-02 | 2006-05-11 | Gangagen Life Sciences Inc. | Encapsulated bacteriophage formulation |
| CA2491665A1 (en) * | 2004-12-24 | 2006-06-24 | Louis Cartilier | Tablet formulation for the sustained release of active substances |
| CA2616416A1 (en) | 2005-09-09 | 2007-05-03 | Labopharm, Inc. | Trazodone composition for once a day adminisitiation |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| WO2007055329A1 (en) * | 2005-11-11 | 2007-05-18 | Asahi Kasei Chemicals Corporation | Controlled release solid preparation |
| JP5122436B2 (en) * | 2006-03-14 | 2013-01-16 | 国立大学法人 奈良先端科学技術大学院大学 | Novel heparin substitute material and method for producing the same |
| US8124598B2 (en) * | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
| EP2068828A2 (en) * | 2006-09-29 | 2009-06-17 | SurModics, Inc. | Biodegradable ocular implants and methods for treating ocular conditions |
| RU2469718C2 (en) * | 2007-10-16 | 2012-12-20 | Лабофарм Инк. | Two-layer composition for continuous release of acetaminophen and tramadol |
| JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
| ES2369868T3 (en) * | 2007-12-28 | 2011-12-07 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | SLOW RELEASE FORMULATION BASED ON A GLUCOGEN AND ALGINATE ASSOCIATION. |
| CA2732131A1 (en) | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
| US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| BRPI1006902A2 (en) | 2009-01-23 | 2016-02-16 | Aziende Chimiche Riunte Angelini Francesco A C R A F S P A | controlled release pharmaceutical or food formulation, process for producing a pharmaceutical or food form, controlled release system, and use of a controlled release system |
| US20120009261A1 (en) | 2010-07-06 | 2012-01-12 | Grünenthal GmbH | Novel gastro-retentive dosage forms |
| US20120015031A1 (en) | 2010-07-14 | 2012-01-19 | Grunenthal Gmbh | Novel gastro-retentive dosage forms |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| WO2015073736A1 (en) | 2013-11-13 | 2015-05-21 | Arbor Pharmaceuticals, Llc | Methods and compositions for treating adhd |
| EP3316862A4 (en) | 2015-07-02 | 2019-02-06 | University of Louisville Research Foundation, Inc. | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622677A (en) * | 1969-07-07 | 1971-11-23 | Staley Mfg Co A E | Compressed tablets containing compacted starch as binder-disintegrant ingredient |
| US4088798A (en) * | 1975-11-11 | 1978-05-09 | Sandoz, Inc. | Methods for the preparation of controlled gastric residence time medicament formulations |
| US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
| DE3045135A1 (en) * | 1980-11-29 | 1982-06-09 | Sandoz-Patent-GmbH, 7850 Lörrach | BODEGRADABLE POLYMERS CONTAINING PHARMACEUTICAL COMPOSITIONS |
| US4369308A (en) * | 1981-07-24 | 1983-01-18 | National Starch And Chemical Corporation | Low swelling starches as tablet disintegrants |
| US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
| GB8319766D0 (en) * | 1983-07-22 | 1983-08-24 | Graham N B | Controlled release device |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4933185A (en) * | 1986-09-24 | 1990-06-12 | Massachusetts Institute Of Technology | System for controlled release of biologically active compounds |
| US4761289A (en) * | 1986-10-10 | 1988-08-02 | International Minerals & Chemical Corp. | Sustained release implant and method for preparing same |
| US4755397A (en) * | 1986-12-24 | 1988-07-05 | National Starch And Chemical Corporation | Starch based particulate encapsulation process |
| US4812445A (en) * | 1987-02-06 | 1989-03-14 | National Starch And Chemical Corporation | Starch based encapsulation process |
| GB8812490D0 (en) * | 1988-05-26 | 1988-06-29 | Agricultural & Food Res | Delayed release formulations |
-
1991
- 1991-05-03 CA CA002041774A patent/CA2041774C/en not_active Expired - Lifetime
-
1994
- 1994-02-09 US US08/194,126 patent/US5456921A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5456921A (en) | 1995-10-10 |
| CA2041774A1 (en) | 1992-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2041774C (en) | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds | |
| CA1201064A (en) | Constant release rate solid oral dosage formulations of drugs having a pk.sub.a7-10 and an aqueous solubility of 15-100 g/ml water | |
| EP0250374B1 (en) | Therapeutic system for controlled release of drugs | |
| AT398165B (en) | METHOD FOR PRODUCING A PHARMACEUTICAL CAPSULE FOR ORAL ADMINISTRATION WITH DELAYED ACTIVE SUBSTANCE RELEASE OR. COMBINED DELAYED / RAPID RELEASE OF ACTIVE SUBSTANCE | |
| US4842866A (en) | Slow release solid preparation | |
| KR0184308B1 (en) | Controlled release verapamil tablet | |
| DE69913197T2 (en) | SODIUM HYDROGEN DIVAL PROGRAM FORMULATIONS WITH CONTROLLED RELEASE | |
| AT398166B (en) | METHOD FOR PRODUCING A PHARMACEUTICAL CAPSULE FOR THE ORAL ADMINISTRATION OF NITROFURANTOIN (SALTS, HYDRATES, COMPLEXES) | |
| DE4413350A1 (en) | Retard matrix pellets and process for their production | |
| JPS61251617A (en) | Composition for conditioning and releasing one or more active components into liquid and method of conditioning same | |
| EP0669129A2 (en) | Expandable release controlled medicaments | |
| WO1998010754A1 (en) | Fast decomposing pellets | |
| JPH08507769A (en) | Crosslinked amylose as tablet binder / disintegrant | |
| Alhalmi et al. | Sustained release matrix system: an overview | |
| HU193731B (en) | Process for preparing galenic form comprising polycaprolactone-based, neutral matrix suitable for the oral dosage of medicines | |
| EP0691843A1 (en) | RETARDED-ACTION MICROTABLET MADE OF -g(b)-PHENYLPROPIOPHENONE DERIVATIVES | |
| Rahman et al. | Formulation and Evaluation of Bi-layered SustainedRelease Matrix Tablets of Tramadol Hydrochloride | |
| EP0088098B1 (en) | Composition and method for the preparation of tablets which rapidly disintegrate in an aqueous medium | |
| Nokhodchi et al. | Studies on controlled-release formulations of diclofenac sodium | |
| AU728754B2 (en) | Compact member comprising a plurality of porous cellulose matrices, (PCMs), method of manufacturing and use thereof | |
| WO2001087228A2 (en) | Sustained release pharmaceutical composition containing glipizide and method for producing same | |
| Wang | Compressed poly (vinyl alcohol)‐polycaprolactone admixture as a model to evaluate erodible implants for sustained drug delivery | |
| JP2001504807A (en) | Oral medicament comprising at least one pharmaceutically active compound in a matrix swellable in an aqueous medium | |
| ES2272527T3 (en) | MODIFIED RELEASE FORMULATION. | |
| Ayesha Farhana et al. | Sustained release of verapamil hydrochloride from sodium alginate microcapsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |